A comparative study of 14‐day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first‐lineHelicobacter pyloriinfection eradication: A randomized trial-Reference-Cited by-同舟云学术

A comparative study of 14‐day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first‐lineHelicobacter pyloriinfection eradication: A randomized trial

Published:2020-10-11 Issue:6 Volume:25 Page:
ISSN:1083-4389
Container-title:Helicobacter
language:en
Short-container-title:Helicobacter

Author:

Song Zhiqiang¹,Zhou Liya¹^ORCID,Xue Yan¹^ORCID,Suo Baojun¹,Tian Xueli¹,Niu Zhanyue¹^ORCID

Affiliation:

1. Department of Gastroenterology Peking University Third Hospital Beijing China

Funder

National Natural Science Foundation of China

AstraZeneca

Publisher

Wiley

Subject

Infectious Diseases,Gastroenterology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hel.12762

Reference38 articles.

1. Helicobacter pylori treatment in the era of increasing antibiotic resistance

2. Prospective multi-region study on primary antibiotic resistance of Helicobacter pylori strains isolated from Chinese patients

3. Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions

4. Management ofHelicobacter pyloriinfection—the Maastricht IV/ Florence Consensus Report

5. Tailored versus Triple plus Bismuth or Concomitant Therapy as InitialHelicobacter pyloriTreatment: A Randomized Trial

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of vonoprazan bismuth‐containing triple therapy with quadruple therapy in Helicobacter pylori‐infected treatment‐naive patients: a prospective multicenter randomized controlled trial;Journal of Gastroenterology and Hepatology;2024-07-16

2. Fourteen‐Day Tegoprazan–Amoxicillin Dual Therapy as the First‐Line Treatment of Helicobacter pylori Infection (SHARE2301): A Multicenter, Noninferiority, Randomized Clinical Trial;Helicobacter;2024-05

3. Application of cefuroxime in the eradication therapy of Helicobacter pylori infection: A review article;Helicobacter;2024-03

4. High‐dose dual therapy versus bismuth‐containing quadruple therapy for the eradication of Helicobacter pylori: A systematic review and meta‐analysis;Journal of Digestive Diseases;2024-03

5. Clarifying varied Helicobacter pylori eradication therapies: A comprehensive review;Helicobacter;2024-01